Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Erivedge (Genentech)
(https://erivedge.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Erivedge® (vismodegib) | Advanced Basal Cell Carcinoma (aBCC) Treatment (https://erivedge.com)
Title
Erivedge® (vismodegib) | Advanced Basal Cell Carcinoma (aBCC) Treatment
Meta
Learn about Erivedge® (vismodegib) as a basal cell carcinoma treatment option for both metastatic and locally advanced carcinoma. See full safety and Boxed Warning for more information.
H1 Erivedge
H2 Real Erivedge Patient Stories
H2 How Erivedge Works
H2 Financial Assistance Options
H3 What is the most important information I should know about Erivedge?
Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects.
H3 For females who can become pregnant:
H3 For males:
H3 Pregnancy Exposure Registry:
H3 Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including:
H3 What should I avoid while taking Erivedge?
H3 What are the possible side effects of Erivedge?
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 Important Safety Information and Indication
H5 Because there’s more to you than your advanced basal cell carcinoma.
H5 Because there’s more to you than your advanced basal cell carcinoma.
H5 Because there’s more to you than your advanced basal cell carcinoma.
H5 Because there’s more to you than your advanced basal cell carcinoma.
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_REPEATED Important Safety Information | Erivedge® (vismodegib) (https://erivedge.com/patient/side-effects/important-safety-information.html)
Title
Important Safety Information | Erivedge® (vismodegib)
Meta
Read important safety information for Erivedge (visomodegib). See full safety & Boxed Warning.
H1 Select Important Safety Information & Indication
H2 Indication
H2 Serious Side Effects
H2 Important Safety Information
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 Quick Links
H5 What is the most important information I should know about Erivedge?
H5 For females who can become pregnant:
H5 For males:
H5 Pregnancy Exposure Registry:
H5 Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including:
H5 What should I avoid while taking Erivedge?
H5 What are the possible side effects of Erivedge?
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_HEADING_REPEATED_BODY How Erivedge Works | Erivedge® (vismodegib) (https://erivedge.com/patient/about-erivedge/how-it-works.html)
Title
How Erivedge Works | Erivedge® (vismodegib)
Meta
Find out how Erivedge® (vismodegib) works to treat advanced basal cell carcinoma. See full safety & Boxed Warning.
H1 How Erivedge Works
H2 Erivedge Patient Support Line*
H3 What is the most important information I should know about Erivedge?
Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects.
H3 For females who can become pregnant:
H3 For males:
H3 Pregnancy Exposure Registry:
H3 Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including:
H3 What should I avoid while taking Erivedge?
H3 What are the possible side effects of Erivedge?
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 How Erivedge is designed to work
H4 Important Safety Information and Indication
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_HEADING_REPEATED_BODY Real Patient Stories | Erivedge® (vismodegib) (https://erivedge.com/patient/results-with-erivedge/patient-stories.html)
Title
Real Patient Stories | Erivedge® (vismodegib)
Meta
Explore results from real people who were treated with Erivedge® (vismodegib). See full safety & Boxed Warning.
H1 Real Patient Stories
H2 Meet Matt and Marsha, 2 patients from the Erivedge clinical study
H2 Matt, age 54
H2 Marsha, age 75
H3 Matt’s Treatment Journey
H3 Matt’s Treatment Journey
H3 Marsha’s Treatment Journey
H3 What is the most important information I should know about Erivedge?
Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects.
H3 For females who can become pregnant:
H3 For males:
H3 Pregnancy Exposure Registry:
H3 Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including:
H3 What should I avoid while taking Erivedge?
H3 What are the possible side effects of Erivedge?
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 Important Safety Information and Indication
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://erivedge.com) Erivedge® (vismodegib) | Advanced Basal Cell Carcinoma (aBCC) Treatment
[H1] Erivedge [H5] Because there’s more to you than your advanced basal cell carcinoma. Reframe your treatment experience with the #1 most-prescribed oral medication for advanced basal cell carcinoma.* Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. *According to IQVIA real-world prescription data of FDA-approved treatments for aBCC between February 2012 and August 2025. Model is not an actual patient. [H1] Erivedge [H5] Because there’s more to you than your advanced basal cell carcinoma. Reframe your treatment experience with the #1 most-prescribed oral medication for advanced basal cell carcinoma.* Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. *According to IQVIA real-world prescription data of FDA-approved treatments for aBCC between February 2012 and August 2025. Model is not an actual patient. [H1] Erivedge [H5] Because there’s more to you than your advanced basal cell carcinoma. Reframe your treatment experience with the #1 most-prescribed oral medication for advanced basal cell carcinoma.* Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. *According to IQVIA real-world prescription data of FDA-approved treatments for advanced basal cell carcinoma between February 2012 and November 2021. [H1] Erivedge [H5] Because there’s more to you than your advanced basal cell carcinoma. Reframe your treatment experience with the #1 most-prescribed oral medication for advanced basal cell carcinoma.* Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. *According to IQVIA real-world prescription data of FDA-approved treatments for advanced basal cell carcinoma between February 2012 and November 2021. Model is not an actual patient. [IMG: Real Erivedge Patient Stories] [H2] Real Erivedge Patient Stories Meet patients who were treated with Erivedge [IMG: How Erivedge Works] [H2] How Erivedge Works Learn how Erivedge is designed to work [IMG: Financial Assistance Options] [H2] Financial Assistance Options Discover financial support programs that may be available to you Erivedge® (vismodegib) is a prescription medicine designed to treat adults with advanced basal cell carcinoma (BCC) that has spread to other parts of the body, returned after surgery, or cannot be treated with surgery or radiation. ERIVEDGE is not indicated for pediatric patients. It is not known if ERIVEDGE is safe and effective in children. Erivedge is designed to work by interrupting signals in certain cells of the body that can cause BCC to grow. Erivedge is administered daily as an oral capsule. It is important to take Erivedge exactly as your doctor tells you. Common side effects of Erivedge include muscle spasms, hair loss, loss or changes in how things taste, weight loss, tiredness, nausea or vomiting, diarrhea, decreased appetite, constipation, and joint pain. Erivedge can cause serious side effects such as embryo-fetal toxicity, severe skin reactions, and bone growth abnormalities. [H4] Important Safety Information and Indication Back to Top [H1] Indication Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. [H1] Serious Side Effects Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H1] Important Safety Information [H3] What is the most important information I should know about Erivedge? Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H3] For females who can become pregnant: You should talk with your healthcare provider about the risks of Erivedge to your unborn child Your healthcare provider will do a pregnancy test within 7 days before you start taking Erivedge In order to avoid pregnancy, you should use birth control during treatment and for 24 months after your final dose of Erivedge. Talk with your healthcare provider about what birth control method is right for you during this time Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed Tell your healthcare provider right away if you become pregnant or think that you may be pregnant [H3] For males: Erivedge is present in semen. Do not donate semen while you are taking Erivedge and for 3 months after your final dose You should always use a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with Erivedge, and for 3 months after your final dose to protect your female partner from being exposed to Erivedge Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking Erivedge [H3] Pregnancy Exposure Registry: There is a Pregnancy Exposure Registry for females taking Erivedge who become pregnant. The purpose of this registry is to monitor the health of you and your unborn baby. If you think that you or your female partner may have been exposed to Erivedge during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with Erivedge, you or your healthcare provider should report your pregnancy to Genentech at (888) 835-2555. [H3] Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including: If you are pregnant or plan to become pregnant If you are breastfeeding or plan to breastfeed. It is not known if Erivedge passes into your breast milk. You should not breastfeed during treatment and for 24 months after your final dose of Erivedge. Talk to your healthcare provider about the best way to feed your baby during this time About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements [H3] What should I avoid while taking Erivedge? Do not donate blood or blood products while you are taking Erivedge and for 24 months after your final dose Do not donate semen while you are taking Erivedge and for 3 months after your final dose [H3] What are the possible side effects of Erivedge? Severe skin reactions: Severe skin reactions have happened in some people taking Erivedge. You may need to be treated in a hospital because these severe skin reactions can be life-threatening or lead to death Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including: Blisters or peeling of your skin Blisters on your lip, or around your mouth or eyes Mouth sores or genital sores High fever or flu-like symptoms Enlarged lymph nodes Skin pain and burning Your healthcare provider may permanently stop Erivedge if you develop a severe skin reaction. Muscle problems: Muscle problems are common with Erivedge, but can also sometimes be serious. Erivedge can increase your risk of muscle spasms or muscle pain. Tell your healthcare provider right away if you develop any new or worsening muscle pain, tenderness, or weakness during or after treatment with Erivedge. Your healthcare provider should do a blood test to check for muscle problems and to check your kidney function before you start taking Erivedge, and as needed during treatment if you develop muscle problems Bone growth problems: Bone growth problems have happened in children who have been exposed to Erivedge. These problems may continue even after stopping treatment with Erivedge The most common side effects of Erivedge are: Muscle spasms Hair loss Change in how things taste or loss of taste Weight loss Tiredness Nausea Diarrhea Decreased appetite Constipation Joint pain Vomiting Erivedge can cause absence of menstrual periods (amenorrhea) in females who are able to become pregnant. It is not known if amenorrha is permanent. Talk to your healthcare provided if you have concerns about fertility. These are not all of the possible side effects of Erivedge. Because everyone is different, it is not possible to predict what side effects any one person will have or how severe they may be. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see full Prescribing Information for additional Important Safety Information, including serious side effects, and the Medication Guide.
10260 chars
SUB-PAGE (https://erivedge.com/patient/side-effects/important-safety-information.html) Important Safety Information | Erivedge® (vismodegib)
[H1] Select Important Safety Information & Indication [H4] Quick Links Indication Serious Side Effects Important Safety Information [H2] Indication Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. [H2] Serious Side Effects Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H2] Important Safety Information [H5] What is the most important information I should know about Erivedge? Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H5] For females who can become pregnant: You should talk with your healthcare provider about the risks of Erivedge to your unborn child Your healthcare provider will do a pregnancy test within 7 days before you start taking Erivedge In order to avoid pregnancy, you should use birth control during treatment and for 24 months after your final dose of Erivedge. Talk with your healthcare provider about what birth control method is right for you during this time Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed Tell your healthcare provider right away if you become pregnant or think that you may be pregnant [H5] For males: Erivedge is present in semen. Do not donate semen while you are taking Erivedge and for 3 months after your final dose You should always use a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with Erivedge, and for 3 months after your final dose to protect your female partner from being exposed to Erivedge Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking Erivedge [H5] Pregnancy Exposure Registry: There is a Pregnancy Exposure Registry for females taking Erivedge who become pregnant. The purpose of this registry is to monitor the health of you and your unborn baby. If you think that you or your female partner may have been exposed to Erivedge during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with Erivedge, you or your healthcare provider should report your pregnancy to Genentech at (888) 835-2555. [H5] Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including: If you are pregnant or plan to become pregnant If you are breastfeeding or plan to breastfeed. It is not known if Erivedge passes into your breast milk. You should not breastfeed during treatment and for 24 months after your final dose of Erivedge. Talk to your healthcare provider about the best way to feed your baby during this time About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements [H5] What should I avoid while taking Erivedge? Do not donate blood or blood products while you are taking Erivedge and for 24 months after your final dose Do not donate semen while you are taking Erivedge and for 3 months after your final dose [H5] What are the possible side effects of Erivedge? Severe skin reactions: Severe skin reactions have happened in some people taking Erivedge. You may need to be treated in a hospital because these severe skin reactions can be life-threatening or lead to death Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including: Blisters or peeling of your skin Blisters on your lip, or around your mouth or eyes Mouth sores or genital sores High fever or flu-like symptoms Enlarged lymph nodes Skin pain and burning Your healthcare provider may permanently stop Erivedge if you develop a severe skin reaction. Muscle problems: Muscle problems are common with Erivedge, but can also sometimes be serious. Erivedge can increase your risk of muscle spasms or muscle pain. Tell your healthcare provider right away if you develop any new or worsening muscle pain, tenderness, or weakness during or after treatment with Erivedge. Your healthcare provider should do a blood test to check for muscle problems and to check your kidney function before you start taking Erivedge, and as needed during treatment if you develop muscle problems Bone growth problems: Bone growth problems have happened in children who have been exposed to Erivedge. These problems may continue even after stopping treatment with Erivedge The most common side effects of Erivedge are: Muscle spasms Hair loss Change in how things taste or loss of taste Weight loss Tiredness Nausea Diarrhea Decreased appetite Constipation Joint pain Vomiting Erivedge can cause absence of menstrual periods (amenorrhea) in females who are able to become pregnant. It is not known if amenorrha is permanent. Talk to your healthcare provided if you have concerns about fertility. These are not all of the possible side effects of Erivedge. Because everyone is different, it is not possible to predict what side effects any one person will have or how severe they may be. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see full Prescribing Information for additional Important Safety Information, including serious side effects, and the Medication Guide. NEXT: Clinical Trials
5885 chars
SUB-PAGE (https://erivedge.com/patient/about-erivedge/how-it-works.html) How Erivedge Works | Erivedge® (vismodegib)
Print Page [H1] How Erivedge Works Before starting treatment, it is important to understand how Erivedge may work inside the body. [H4] How Erivedge is designed to work [IMG: Infographic demonstrating how Erivedge works to interrupt basal cell carcinoma cell growth signals] BCC = basal cell carcinoma. Targeted therapy can affect both cancer and healthy cells. [IMG: Erivedge Patient Support Line] [H2] Erivedge Patient Support Line* One-on-one phone support with Patient Support Specialists is available Monday through Friday, 9 AM to 8 PM ET, at 855-7-ERIVEDGE or 855-737-4833. *The Erivedge Patient Support Line is for educational purposes only and is not intended to provide medical advice or replace the medical advice of your doctor or other healthcare provider, who should always be your primary source of information about your health, diagnosis, and treatment. NEXT: Erivedge Side Effects & Tips [H4] Important Safety Information and Indication Back to Top [H1] Indication Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. [H1] Serious Side Effects Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H1] Important Safety Information [H3] What is the most important information I should know about Erivedge? Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H3] For females who can become pregnant: You should talk with your healthcare provider about the risks of Erivedge to your unborn child Your healthcare provider will do a pregnancy test within 7 days before you start taking Erivedge In order to avoid pregnancy, you should use birth control during treatment and for 24 months after your final dose of Erivedge. Talk with your healthcare provider about what birth control method is right for you during this time Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed Tell your healthcare provider right away if you become pregnant or think that you may be pregnant [H3] For males: Erivedge is present in semen. Do not donate semen while you are taking Erivedge and for 3 months after your final dose You should always use a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with Erivedge, and for 3 months after your final dose to protect your female partner from being exposed to Erivedge Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking Erivedge [H3] Pregnancy Exposure Registry: There is a Pregnancy Exposure Registry for females taking Erivedge who become pregnant. The purpose of this registry is to monitor the health of you and your unborn baby. If you think that you or your female partner may have been exposed to Erivedge during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with Erivedge, you or your healthcare provider should report your pregnancy to Genentech at (888) 835-2555. [H3] Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including: If you are pregnant or plan to become pregnant If you are breastfeeding or plan to breastfeed. It is not known if Erivedge passes into your breast milk. You should not breastfeed during treatment and for 24 months after your final dose of Erivedge. Talk to your healthcare provider about the best way to feed your baby during this time About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements [H3] What should I avoid while taking Erivedge? Do not donate blood or blood products while you are taking Erivedge and for 24 months after your final dose Do not donate semen while you are taking Erivedge and for 3 months after your final dose [H3] What are the possible side effects of Erivedge? Severe skin reactions: Severe skin reactions have happened in some people taking Erivedge. You may need to be treated in a hospital because these severe skin reactions can be life-threatening or lead to death Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including: Blisters or peeling of your skin Blisters on your lip, or around your mouth or eyes Mouth sores or genital sores High fever or flu-like symptoms Enlarged lymph nodes Skin pain and burning Your healthcare provider may permanently stop Erivedge if you develop a severe skin reaction. Muscle problems: Muscle problems are common with Erivedge, but can also sometimes be serious. Erivedge can increase your risk of muscle spasms or muscle pain. Tell your healthcare provider right away if you develop any new or worsening muscle pain, tenderness, or weakness during or after treatment with Erivedge. Your healthcare provider should do a blood test to check for muscle problems and to check your kidney function before you start taking Erivedge, and as needed during treatment if you develop muscle problems Bone growth problems: Bone growth problems have happened in children who have been exposed to Erivedge. These problems may continue even after stopping treatment with Erivedge The most common side effects of Erivedge are: Muscle spasms Hair loss Change in how things taste or loss of taste Weight loss Tiredness Nausea Diarrhea Decreased appetite Constipation Joint pain Vomiting Erivedge can cause absence of menstrual periods (amenorrhea) in females who are able to become pregnant. It is not known if amenorrha is permanent. Talk to your healthcare provided if you have concerns about fertility. These are not all of the possible side effects of Erivedge. Because everyone is different, it is not possible to predict what side effects any one person will have or how severe they may be. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see full Prescribing Information for additional Important Safety Information, including serious side effects, and the Medication Guide.
6920 chars
SUB-PAGE (https://erivedge.com/patient/results-with-erivedge/patient-stories.html) Real Patient Stories | Erivedge® (vismodegib)
[H1] Real Patient Stories [H2] Meet Matt and Marsha, 2 patients from the Erivedge clinical study [H3] Matt’s Treatment Journey Matt was diagnosed with locally advanced basal cell carcinoma behind his ear. Learn about his experience and results with Erivedge. Read more [IMG: Baseline basal cell carcinoma lesion behind ear of patient treated with Erivedge] [H3] Marsha’s Treatment Journey Marsha was diagnosed with locally advanced basal cell carcinoma on the mid-shin of her left leg. Learn about her experience and results with Erivedge. Read more [IMG: Baseline basal cell carcinoma lesion on shin of patient treated with Erivedge] [H2] Matt, age 54 Locally advanced basal cell carcinoma behind his ear Baseline [IMG: Baseline basal cell carcinoma lesion behind ear of patient treated with Erivedge] Week 24 [IMG: Basal cell carcinoma lesion behind ear after 24 weeks of treatment with Erivedge] Matt’s history of basal cell carcinoma He was first diagnosed with basal cell carcinoma in 1987 What made Matt eligible for Erivedge? He was not a candidate for surgery or radiation therapy Matt’s treatment journey with Erivedge He started treatment with Erivedge in February 2010 and was treated for 9.6 months In the Erivedge clinical study, the median duration of treatment was 10.2 months (range, 0.7 to 18.7 months) He continued on treatment as of the data cutoff in November 2010 How effective was Erivedge for Matt? He experienced a complete response, which means he had no evidence of basal cell carcinoma at Week 24 of treatment What side effects did Matt experience? He experienced hair loss, a change in how things taste, muscle spasms, nausea, and weight loss Photos are from a real patient. Patient may have had other lesions besides the one shown here. Individual results may vary. Descriptions are based on study investigator assessments. Case studies show results of treatment in specific patients. These cases are for general informational purposes only and are not intended to replace medical advice or your doctor’s medical judgment when it comes to your treatment. Although not shown here, patients with metastatic basal cell carcinoma also participated in the Erivedge clinical study. [H2] Marsha, age 75 Locally advanced basal cell carcinoma on the mid-shin of her left leg Baseline [IMG: Baseline basal cell carcinoma lesion on shin of patient treated with Erivedge] Week 24 [IMG: Basal cell carcinoma lesion on shin after 24 weeks of treatment with Erivedge] Marsha’s history of basal cell carcinoma She was first diagnosed with basal cell carcinoma in 1990 What made Marsha eligible for Erivedge? She was not a candidate for surgery or radiation therapy Marsha’s treatment journey with Erivedge She started treatment with Erivedge in November 2009 and was treated for 12.5 months In the Erivedge clinical study, the median duration of treatment was 10.2 months (range, 0.7 to 18.7 months) She continued on treatment as of the data cutoff in November 2010 What were Marsha’s results with Erivedge? She experienced a non-response, which means she still had evidence of basal cell carcinoma at Week 24 of treatment What side effects did Marsha experience? She experienced a decrease in appetite, reduced sense of taste, muscle spasms, and weight loss Photos are from a real patient. Individual results may vary. Descriptions are based on study investigator assessments. Case studies show results of treatment in specific patients. These cases are for general informational purposes only and are not intended to replace medical advice or your doctor’s medical judgment when it comes to your treatment. Although not shown here, patients with metastatic basal cell carcinoma also participated in the Erivedge clinical study. NEXT: How to take Erivedge [H4] Important Safety Information and Indication Back to Top [H1] Indication Erivedge® (vismodegib) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. [H1] Serious Side Effects Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H1] Important Safety Information [H3] What is the most important information I should know about Erivedge? Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. [H3] For females who can become pregnant: You should talk with your healthcare provider about the risks of Erivedge to your unborn child Your healthcare provider will do a pregnancy test within 7 days before you start taking Erivedge In order to avoid pregnancy, you should use birth control during treatment and for 24 months after your final dose of Erivedge. Talk with your healthcare provider about what birth control method is right for you during this time Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed Tell your healthcare provider right away if you become pregnant or think that you may be pregnant [H3] For males: Erivedge is present in semen. Do not donate semen while you are taking Erivedge and for 3 months after your final dose You should always use a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with Erivedge, and for 3 months after your final dose to protect your female partner from being exposed to Erivedge Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking Erivedge [H3] Pregnancy Exposure Registry: There is a Pregnancy Exposure Registry for females taking Erivedge who become pregnant. The purpose of this registry is to monitor the health of you and your unborn baby. If you think that you or your female partner may have been exposed to Erivedge during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with Erivedge, you or your healthcare provider should report your pregnancy to Genentech at (888) 835-2555. [H3] Before taking Erivedge, tell your healthcare provider about all of your medical conditions, including: If you are pregnant or plan to become pregnant If you are breastfeeding or plan to breastfeed. It is not known if Erivedge passes into your breast milk. You should not breastfeed during treatment and for 24 months after your final dose of Erivedge. Talk to your healthcare provider about the best way to feed your baby during this time About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements [H3] What should I avoid while taking Erivedge? Do not donate blood or blood products while you are taking Erivedge and for 24 months after your final dose Do not donate semen while you are taking Erivedge and for 3 months after your final dose [H3] What are the possible side effects of Erivedge? Severe skin reactions: Severe skin reactions have happened in some people taking Erivedge. You may need to be treated in a hospital because these severe skin reactions can be life-threatening or lead to death Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including: Blisters or peeling of your skin Blisters on your lip, or around your mouth or eyes Mouth sores or genital sores High fever or flu-like symptoms Enlarged lymph nodes Skin pain and burning Your healthcare provider may permanently stop Erivedge if you develop a severe skin reaction. Muscle problems: Muscle problems are common with Erivedge, but can also sometimes be serious. Erivedge can increase your risk of muscle spasms or muscle pain. Tell your healthcare provider right away if you develop any new or worsening muscle pain, tenderness, or weakness during or after treatment with Erivedge. Your healthcare provider should do a blood test to check for muscle problems and to check your kidney function before you start taking Erivedge, and as needed during treatment if you develop muscle problems Bone growth problems: Bone growth problems have happened in children who have been exposed to Erivedge. These problems may continue even after stopping treatment with Erivedge The most common side effects of Erivedge are: Muscle spasms Hair loss Change in how things taste or loss of taste Weight loss Tiredness Nausea Diarrhea Decreased appetite Constipation Joint pain Vomiting Erivedge can cause absence of menstrual periods (amenorrhea) in females who are able to become pregnant. It is not known if amenorrha is permanent. Talk to your healthcare provided if you have concerns about fertility. These are not all of the possible side effects of Erivedge. Because everyone is different, it is not possible to predict what side effects any one person will have or how severe they may be. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see full Prescribing Information for additional Important Safety Information, including serious side effects, and the Medication Guide.
9859 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
2Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /patient/side-effects/important-safety-information.html | 0 | 0 |
| /patient/about-erivedge/how-it-works.html | 2 | 0 |
| /patient/results-with-erivedge/patient-stories.html | 0 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
[
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
},
{
"@context": "schema.org",
"@type": "MedicalWebPage",
"url": "https://www.erivedge.com/",
"description": "Learn about Erivedge® (vismodegib) as a basal cell carcinoma treatment option for both metastatic and locally advanced carcinoma. See full safety and Boxed Warning for more information.",
"MedicalAudience": "https://schema.org/Patient",
"about": [
{
"@type": "Drug",
"dosageForm": [
"Capsule"
],
"administrationRoute": [
"Oral"
]
},
{
"@type": "MedicalCondition",
"alternateName": [
"aBCC"
]
}
]
}
]
/patient/side-effects/important-safety-information.html
[
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
},
{
"@context": "schema.org",
"@type": "MedicalWebPage",
"url": "https://www.erivedge.com/patient/side-effects/important-safety-information.html",
"description": "Read important safety information for Erivedge (visomodegib). See full safety & Boxed Warning. ",
"MedicalAudience": "https://schema.org/Patient",
"about": [
{
"@type": "Drug",
"name": "Erivedge",
"nonProprietaryName": "Vismodegib",
"dosageForm": [
"Capsule"
],
"administrationRoute": [
"Oral"
]
},
{
"@type": "MedicalCondition",
"name": "Advanced Basal Cell Carcinoma",
"alternateName": [
"aBCC"
]
}
]
}
]
/patient/about-erivedge/how-it-works.html
[
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
},
{
"@context": "schema.org",
"@type": "MedicalWebPage",
"url": "https://www.erivedge.com/patient/about-erivedge/how-it-works.html",
"description": "Find out how Erivedge® (vismodegib) works to treat advanced basal cell carcinoma. See full safety & Boxed Warning.",
"MedicalAudience": "https://schema.org/Patient",
"about": [
{
"@type": "Drug",
"name": "Erivedge",
"nonProprietaryName": "Vismodegib",
"dosageForm": [
"Capsule"
],
"administrationRoute": [
"Oral"
]
},
{
"@type": "MedicalCondition",
"name": "Advanced Basal Cell Carcinoma",
"alternateName": [
"aBCC"
]
}
]
}
]
/patient/results-with-erivedge/patient-stories.html
[
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
},
{
"@context": "schema.org",
"@type": "MedicalWebPage",
"url": "https://www.erivedge.com/patient/results-with-erivedge/patient-stories.html",
"description": "Explore results from real people who were treated with Erivedge® (vismodegib). See full safety & Boxed Warning.",
"MedicalAudience": "https://schema.org/Patient",
"about": [
{
"@type": "Drug",
"name": "Erivedge",
"nonProprietaryName": "Vismodegib",
"dosageForm": [
"Capsule"
],
"administrationRoute": [
"Oral"
]
},
{
"@type": "MedicalCondition",
"name": "Advanced Basal Cell Carcinoma",
"alternateName": [
"aBCC"
]
}
]
}
]
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: Erivedge (Genentech) (erivedge.com)
https://erivedge.com
📍 Industry: Medical Devices, Pharma & Biotech
20
BS / 100
A high-authority, low-BS site that is legally tethered to reality by FDA regulations. Its only significant bullshit is the ‘marketing film’ of repetitive emotional taglines and the use of 16-year-old case studies to represent a modern market leader.
Info Density
Power-words vs. Substance ratio.
11
37% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
2
10% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
5
25% BS
Commodity Fingerprint
Detection of industry clichés/templates.
2
13% BS
Identity & Authority
Expert verifiability & Schema depth.
0
0% BS
1. Replace the 2010 case studies with patients from the 2021-2025 IQVIA data set to eliminate temporal drift. 2. Remove the 4x repetition of the H5 tagline on the homepage to improve heading information density. 3. Add direct outbound links to ClinicalTrials.gov for the specific studies mentioned to move from ‘Trust Theatre’ to ‘Verified Proof’. 4. Standardize the disclaimer across pages to clarify where models are used versus actual trial participants.
The site perfectly aligns with the Pharma & Biotech industry, specifically the oncology therapeutic area. It utilizes dense regulatory language, FDA-mandated safety disclosures (Boxed Warnings), and pharmacovigilance mechanisms consistent with a prescription drug platform.
“The score of 20 is primarily driven by the Information Density pillar (stale 2010 data and repetitive taglines) and the Trust and Proof pillar (internal reviews without outbound verification). The site scores 0 in Identity and Authority due to its robust, verified corporate and regulatory footprint.”
Verified Analysis Date: May 30, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Erivedge (Genentech), captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Erivedge (Genentech): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://erivedge.com to view the most current version of its content and learn from the source what this company is about and what it offers.